Is there a relationship between TSH levels and diabetic retinopathy in the Caucasian population?
ABSTRACT A retrospective study was performed to investigate whether the relationship between subclinical hypothyroidism (SCH) and diabetic retinopathy (DR) reported in Asiatic type 2 diabetic populations also occurs in the Caucasian population. We could not find any relationship between either TSH levels or the presence of SCH and DR.
- SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: To find the associations between diabetic retinopathy and age at diagnosis, C-peptide level and thyroid-stimulating hormone (TSH) level in Chinese type 2 diabetes mellitus. 3100 hospitalized type 2 diabetic patients in Peking University People's Hospital were included in this retrospective study. Their medical history and the laboratory data were collected. All the patients received examination of diabetic retinopathy (DR) by professional ophthalmologist. Comparisons among patients with NDR, NPDR and PDR showed that with the progression of diabetic retinopathy, patients turned to have older age but younger age at diagnosis of diabetes, and have higher SBP, longer duration of diabetes, higher mean HbA1c but lower fasting and 2 hours postprandial C-peptide level. Moreover, with the progression of diabetic retinopathy, patients turned to have higher prevalence of primary hypertension, higher prevalence of peripheral vascular sclerosis, higher proportion with insulin treatment. TSH level was comparable among the three groups of patients. Association analysis showed that after adjusting for age, sex, duration of diabetes, body mass index, HbA1c, blood pressure and albuminurea creatinine ratio and insulin treatment, age at diagnosis (OR 0.888, 95%CI 0.870-0.907, p = 0.00) and postprandial C-peptide (OR 0.920, 95%CI 0.859-0.937, p = 0.00) are the independent associated factors of DR in Chinese type 2 diabetes. According to the results, postprandial C-peptide level and age at diabetes may be two independent associated factors with DR in Chinese type 2 diabetes. The lower level of postprandial C-peptide, the younger age at diagnosis, may indicate the higher prevalence of DR.PLoS ONE 03/2014; 9(3):e91174. DOI:10.1371/journal.pone.0091174 · 3.53 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: AimsTo investigate if thyroid-stimulating hormone (TSH) levels are associated with any differences in glycaemic control or diabetes-related complications in individuals with Type 1 diabetes.Methods This observational, cross-sectional and multicentre study included patients with Type 1 diabetes for ≥ 5 years, with a recent thyroid-stimulating hormone measurement and without a known previous thyroid disease. Patients were divided into three groups according to thyroid-stimulating hormone levels: 0.4–2.5 mU/l; 2.5–4.4 mU/l; and ≥ 4.5 mU/l.ResultsWe included 1205 individuals with a mean ± sd age of 23.8±11.3 years. Seven patients had thyroid-stimulating hormone levels <0.4 mU/l and were excluded from the comparison between groups. HbA1c levels, systolic and diastolic blood pressure, LDL cholesterol and disease duration were similar in all groups (P=0.893, P=0.548, P=0.461, P=0.575 and P=0.764, respectively). The rates of diabetic retinopathy and GFR < 60/mL/min/1.73 m2 differed between groups (P=0.006 and P<0.001, respectively) and were lower in those with lower thyroid-stimulating hormone levels. Multivariate analysis confirmed these associations. The frequencies of retinopathy and GFR < 60 mL/min/1.73 m2 were higher not only in patients with thyroid-stimulating hormone ≥ 4.5 mU/l (odds ratio 1.878 and 2.271, respectively) but also in those with thyroid-stimulating hormone levels of 2.5–4.4 mU/l (odds ratio 1.493 and 2.286, respectively), when compared with patients with thyroid-stimulating hormone levels of 0.4–2.5 mU/l.Conclusions Thyroid-stimulating hormone levels of 0.4–2.5 mU/l are associated with a lower risk of diabetic retinopathy and renal failure in individuals with Type 1 diabetes, independently of glycaemic control and duration of the disease.This article is protected by copyright. All rights reserved.Diabetic Medicine 06/2014; 31(12). DOI:10.1111/dme.12530 · 3.06 Impact Factor